Catalyst Wire Dossier Catalyst Wire Dossier

ABP710

ABP710 · Amgen
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ABP710, covering 2019-08-28 to 2019-08-28. Get the full timeline:

Most recent: Clinical Trial Update: Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab [Phase 3]

See pricing